지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.9
- 수록면
- 605 - 613 (9page)
- DOI
- https://doi.org/10.5124/jkma.2021.64.9.605
이용수
초록· 키워드
오류제보하기
Background: The treatment of inflammatory bowel diseases has evolved with the development of anti-tumor necrosis factor agents. Despite the long-term effectiveness, many patients experience primary non-response, secondary loss of response, or intolerance. Therefore, the development of new drugs that act on different inflammatory pathways has become necessary. This review focuses on biologic agents and new therapies for the treatment of inflammatory bowel diseases.
Current Concepts: Vedolizumab, a gut-selective agent that targets α4β7 integrin is effective in both ulcerative colitis and Crohn’s disease. Ustekinumab is a monoclonal antibody that binds to p40 subunit of interleukin-12/ interleukin-23. Ustekinumab is available for the treatment of Crohn’s disease and ulcerative colitis. Tofacitinib is the first Janus kinase inhibitor approved for the treatment of ulcerative colitis. The advantage of tofacitinib is an oral prescription medicine and has rapid action.
Discussion and Conclusion: Since vedolizumab, ustekinumab and tofacitinib are effective agents for the treatment of inflammatory bowel diseases, positioning of old and new biologic agents and small molecules should be determined.
The safety and efficacy of novel and emerging drugs needs to be evaluated in patients with inflammatory bowel disease.
목차
등록된 정보가 없습니다.
참고문헌 (48)
참고문헌 신청
Tomohiro Fukuda / 2019 / Current new challenges in the management of ulcerative colitis / Intestinal research 17(1):36~44
Emiko Mizoguchi / 2020 / Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models / Intestinal research 18(2):151~167
Choon Jin Ooi / 2019 / Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia / Intestinal research 17(3):285~310
Hanauer SB / 2002 / Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial / Lancet 359:1541~1549
Colombel JF / 2007 / Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease : the CHARM trial / Gastroenterology 132:52~65
Emiko Mizoguchi / 2020 / Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models / Intestinal research 18(2):151~167
Choon Jin Ooi / 2019 / Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia / Intestinal research 17(3):285~310
Hanauer SB / 2002 / Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial / Lancet 359:1541~1549
Colombel JF / 2007 / Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease : the CHARM trial / Gastroenterology 132:52~65
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
염증성 장질환의 약물요법
대한의사협회지
2015 .01
-
Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver
2015 .01
-
Trends of inflammatory bowel disease at a tertiary care center in northern India
Intestinal research
2021 .01
-
Precision medicine in inflammatory bowel diseases
Intestinal research
2024 .01
-
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Gut and Liver
2021 .09
-
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Intestinal research
2019 .01
-
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Intestinal research
2023 .01
-
Efficacy evalution of candidate A in DSS-induced inflammatory bowel disease mouse model
한국실험동물학회 학술발표대회 논문집
2022 .07
-
Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
Gut and Liver
2017 .01
-
Prevalence of Inflammatory Bowel Disease Unclassified, as Estimated Using the Revised Porto Criteria, among Korean Pediatric Patients with Inflammatory Bowel Disease
Pediatric Gastroenterology, Hepatology & Nutrition
2024 .07
-
Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease
Gut and Liver
2022 .11
-
Disability Index as a New Outcome Measure in Patients with Inflammatory Bowel Disease
Gut and Liver
2017 .01
-
Benign Colorectal Disease 2 : Inflammatory Bowel Disease
대한외과학회 학술대회 초록집
2016 .11
-
Benign Colorectal Disease 2 : Inflammatory Bowel Disease
대한외과학회 학술대회 초록집
2015 .11
-
염증성 장질환 처방에 대한 네트워크 분석 - K-HERB 데이터베이스를 활용한 예비적 처방 탐색 -
대한예방한의학회지
2024 .08
-
Mitochondrial dysfunction of epithelial cell drives submucosal thickening through inflammatory fibroblasts in ulcerative colitis
한국실험동물학회 학술발표대회 논문집
2025 .02
-
Trends in Healthcare Costs for Inflammatory Bowel Disease in South Korea
Gut and Liver
2020 .01
-
Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing
Intestinal research
2024 .07
-
Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
Intestinal research
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0